Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Overview
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-2138 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-213388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and JAK3 for Crohn’s Diseases and Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise ITK/TSK (Interleukin 2 Inducible T Cell Kise or T Cell Specific Kise or Kise EMT or Tyrosine Protein Kise Lyk or ITK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Dec 07, 2019: Corvus Pharmaceuticals presents preclinical and initial clinical data from the phase 1/1b trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Nov 07, 2019: Corvus Pharmaceuticals to present preclinical and early clinical data from the phase 1/1b trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Feb 14, 2019: Use of gastric acid suppressants may negatively impact survival outcomes in sarcoma patients treated with Pazopanib
Jan 10, 2019: Corvus announces presentation of preclinical data on CPI-818, a first-in-class covalent inhibitor of ITK targeting T-cell lymphomas
Jun 02, 2018: ntOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT
Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079
Apr 01, 2014: Results from phase III patient preference study of GSK’s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced rel cell carcinoma published in Jourl of Clinical Oncology
Mar 31, 2014: Votrient as maintence therapy for advanced ovarian cancer in the EU
Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 07, 2013: GSK seeks additiol indication approval for Votrient from EMA
Jul 11, 2013: GlaxoSmithKline’s cancer drug Votrient receives full EU approval
Jun 01, 2013: GSK’s Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintence Therapy In Women With Advanced Epithelial Ovarian Cancer
Jan 08, 2013: Combition Of Pazopanib And Paclitaxel May Slow Aplastic Thyroid Cancer, Mayo Clinic Study Shows
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aclaris Therapeutics Inc, H2 2019
Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Pipeline by Corvus Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Japan Tobacco Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Principia Biopharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019